On June 11, Celltrion has announced the presentation of preclinical results for its antibody-drug conjugate (ADC) candidate, CT-P73, at the World ADC Asia Summit, held from June 10 to 12 at the Grand Hyatt in Incheon. This conference brings together experts in the ADC field to share the latest technological advancements and developments in this emerging therapeutic modality.
Celltrion revealed the preclinical findings of CT-P73, which targets solid tumors such as cervical cancer, head and neck cancer, and colorectal cancer, in a poster presentation at the summit. CT-P73 is an ADC therapy designed to target a specific tissue factor highly expressed on cancer cells. It uses an antibody linked to a cytotoxic payload, which induces targeted attacks on cancer cells.
The development of CT-P73 incorporates open innovation, applying a novel topoisomerase 1 (TOP1) inhibitor payload, PBX-7016, developed in collaboration with domestic partner Pinobio and derived from camptothecin. This payload is also used in Celltrion’s previously disclosed ADCs, CT-P70 and CT-P71. TOP1 inhibitors work by damaging DNA to kill cancer cells and prevent their spread.
In preclinical studies, CT-P73 demonstrated a favorable therapeutic index, showing low toxicity and superior efficacy. It also confirmed advantageous pharmacokinetic properties due to the stability of its linker. Furthermore, CT-P73 is expected to exhibit a bystander effect, destroying surrounding cancer cells, and excellent tumor penetration.
Based on these findings, Celltrion plans to submit an investigational new drug (IND) application for CT-P73 to regulatory authorities both domestically and internationally as early as this year. The company aims to develop CT-P73 into a "best-in-class" anticancer therapy within its mechanistic class.
A Celltrion representative stated, “The preclinical success of CT-P73 in efficacy and safety metrics provides us with the competitive edge needed to develop this candidate into a best-in-class drug. We are committed to advancing innovative therapies that offer new benefits to patients and advance us as a global leader in novel drug development.”
Looking forward, Celltrion aims to submit IND applications for 13 candidates, including nine in the ADC field and four for multispecific antibodies, by 2028. Leveraging its accumulated expertise in antibody drug development, including creating the world’s first antibody biosimilar, and through bold investments, Celltrion plans to quickly expand its pipeline and establish itself as a leader in breakthrough antibody therapeutics.
